ANT-045
cMET-positive solid tumours
Pre-clinicalActive
Key Facts
About Antikor Biopharma
Antikor Biopharma is a private, preclinical-stage biotech leveraging its proprietary OptiLink platform to develop Fragment Drug Conjugates (FDCs), a novel class of antibody-drug conjugates. The company's technology utilizes smaller, stable antibody fragments designed for superior tumour penetration, faster clearance from healthy tissues, and higher drug payloads, potentially leading to a wider therapeutic index in solid tumours. Based in Cambridge, UK, Antikor is actively seeking partnerships to advance its platform and lead candidate, ANT-045, targeting cMET, while presenting its research at major industry conferences.
View full company profile